BRD8 is a therapeutic vulnerability for overcoming resistance to dual ER/HER2 blockade therapy in HR+/HER2+ breast cancer
RNA-seq (gene expression) · human · 16 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 16 samples: 3 × BT474_DMSO vs 3 × BT474_KO_DMSO vs 3 × BT474_Ner vs 3 × BT474_KO_NerGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast CancerCancer research · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE230328_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA958241 and SRA study SRP433810. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 3 samples read as cases, 6 as controls.
How we read this: 4 replicated groups read from 16 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7213900 BT474_DMSO_Rep_1 BT474_DMSO
- GSM7213901 BT474_DMSO_Rep_2 BT474_DMSO
- GSM7213902 BT474_DMSO_Rep_3 BT474_DMSO
- GSM7213903 BT474_KO_DMSO_Rep_1 BT474_KO_DMSO
- GSM7213904 BT474_KO_DMSO_Rep_2 BT474_KO_DMSO
- GSM7213905 BT474_KO_DMSO_Rep_3 BT474_KO_DMSO
- GSM7213906 BT474_Ner_Rep_1 BT474_Ner
- GSM7213907 BT474_Ner_Rep_2 BT474_Ner
- GSM7213908 BT474_Ner_Rep_3 BT474_Ner
- GSM7213909 BT474_KO_Ner_Rep_1 BT474_KO_Ner
- GSM7213910 BT474_KO_Ner_Rep_2 BT474_KO_Ner
- GSM7213911 BT474_KO_Ner_Rep_3 BT474_KO_Ner
- GSM7213912 1-D: DMSO treated BT474 cells
- GSM7213913 2-F: Fulvestrant treated BT474 cells
- GSM7213914 3-N: Neratinib treated BT474 cells
- GSM7213915 4-F-N: Fulvestrant + neratinib treated BT474 cells
- GSE300628 HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies 60 samples shares her2, therapeutic, resistance
- GSE231525 DUSP6 inhibition overcomes Neuregulin/HER3-driven therapy resistance in HER2+ breast cancer [BT474] 12 samples shares her2, resistance, therapy
- GSE231526 DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer 18 samples shares her2, therapy
- GSE295392 PIKfyve-regulated lipid metabolism as a therapeutic vulnerability in neuroendocrine prostate cancer 82 samples shares vulnerability, therapeutic
- GSE316474 Regulation of melanoma cellular plasticity by the Mediator complex drives therapeutic resistance 66 samples shares therapeutic, resistance
- GSE293952 Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma [bulk RNA-seq] 61 samples shares therapeutic, resistance
- GSE275637 ATF4-Mediated Metabolic Stress Response as a Therapeutic Vulnerability in Chordoma 50 samples shares vulnerability, therapeutic
- GSE294109 Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma [scRNAseq] 25 samples shares therapeutic, resistance
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.